Based on the findings abovementioned, time to treatment, an essential feature of CLL management, was reported to be predicted by the methylation status of SMYD3 gene promoter and UBE2R gene methylation levels [29]. Here, SMYD3 is linked to B-cell chronic lymphocytic leukemia.